The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
 
Rachel Woodford
No Relationships to Disclose
 
Deborah Zhou
No Relationships to Disclose
 
Peey-Sei Kok
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Pfizer
Other Relationship - AstraZeneca (Inst); Roche (Inst)
 
Sally Lord
No Relationships to Disclose
 
Ian Marschner
No Relationships to Disclose
 
Michael Friedlander
Honoraria - AstraZeneca; GlaxoSmithKline; Lilly; MSD; Novartis; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; GlaxoSmithKline; Lilly; MSD; Novartis; Takeda
Speakers' Bureau - ACT Genomics; AstraZeneca
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Chee Khoon Lee
No Relationships to Disclose